GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Piotroski F-Score

The Medicines Co (The Medicines Co) Piotroski F-Score : 0 (As of May. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

The Medicines Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for The Medicines Co's Piotroski F-Score or its related term are showing as below:


The Medicines Co Piotroski F-Score Historical Data

The historical data trend for The Medicines Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Piotroski F-Score Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 2.00 2.00 3.00

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 4.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep19) TTM:Last Year (Sep18) TTM:
Net Income was -42.474 + -59.865 + -60.055 + -73.994 = $-236.39 Mil.
Cash Flow from Operations was -39.027 + -49.823 + -48.775 + -60.711 = $-198.34 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was -0.697 + 0 + 0 + 0 = $-0.70 Mil.
Average Total Assets from the begining of this year (Sep18)
to the end of this year (Sep19) was
(733.737 + 841.686 + 835.853 + 956.273 + 897.27) / 5 = $852.9638 Mil.
Total Assets at the begining of this year (Sep18) was $733.74 Mil.
Long-Term Debt & Capital Lease Obligation was $464.99 Mil.
Total Current Assets was $326.73 Mil.
Total Current Liabilities was $423.14 Mil.
Net Income was -178.26 + 29.149 + -54.197 + -55.634 = $-258.94 Mil.

Revenue was 8.595 + 7.771 + 1.667 + -3.3 = $14.73 Mil.
Gross Profit was -11.843 + 5.034 + -1.264 + -4.19 = $-12.26 Mil.
Average Total Assets from the begining of last year (Sep17)
to the end of last year (Sep18) was
(1006.98 + 872.983 + 861.174 + 795.837 + 733.737) / 5 = $854.1422 Mil.
Total Assets at the begining of last year (Sep17) was $1,006.98 Mil.
Long-Term Debt & Capital Lease Obligation was $669.72 Mil.
Total Current Assets was $187.25 Mil.
Total Current Liabilities was $77.76 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

The Medicines Co's current Net Income (TTM) was -236.39. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

The Medicines Co's current Cash Flow from Operations (TTM) was -198.34. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep18)
=-236.388/733.737
=-0.32216993

ROA (Last Year)=Net Income/Total Assets (Sep17)
=-258.942/1006.98
=-0.25714711

The Medicines Co's return on assets of this year was -0.32216993. The Medicines Co's return on assets of last year was -0.25714711. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

The Medicines Co's current Net Income (TTM) was -236.39. The Medicines Co's current Cash Flow from Operations (TTM) was -198.34. ==> -198.34 > -236.39 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep18 to Sep19
=464.991/852.9638
=0.5451474

Gearing (Last Year: Sep18)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep17 to Sep18
=669.724/854.1422
=0.78408958

The Medicines Co's gearing of this year was 0.5451474. The Medicines Co's gearing of last year was 0.78408958. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep19)=Total Current Assets/Total Current Liabilities
=326.729/423.141
=0.7721516

Current Ratio (Last Year: Sep18)=Total Current Assets/Total Current Liabilities
=187.249/77.757
=2.40813046

The Medicines Co's current ratio of this year was 0.7721516. The Medicines Co's current ratio of last year was 2.40813046. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

The Medicines Co's number of shares in issue this year was 80.129. The Medicines Co's number of shares in issue last year was 73.544. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.697/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-12.263/14.733
=-0.83234915

The Medicines Co's gross margin of this year was . The Medicines Co's gross margin of last year was -0.83234915. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep18)
=0/733.737
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep17)
=14.733/1006.98
=0.01463088

The Medicines Co's asset turnover of this year was 0. The Medicines Co's asset turnover of last year was 0.01463088. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

The Medicines Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The Medicines Co  (NAS:MDCO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


The Medicines Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of The Medicines Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010